Condition: Â HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: Â Drug:Â ZW25Â (Zanidatamab); Â Drug:Â Capecitabine; Â Drug:Â Cisplatin; Â Drug:Â Fluorouracil; Â Drug:Â Leucovorin; Â Drug:Â Oxaliplatin; Â Drug:Â Bevacizumab; Â Drug:Â Gemcitabine
Sponsor:  Zymeworks Inc.
**RECRUITING NOW**
Interventions: Â Drug:Â ZW25Â (Zanidatamab); Â Drug:Â Capecitabine; Â Drug:Â Cisplatin; Â Drug:Â Fluorouracil; Â Drug:Â Leucovorin; Â Drug:Â Oxaliplatin; Â Drug:Â Bevacizumab; Â Drug:Â Gemcitabine
Sponsor:  Zymeworks Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
